Proceedings of the National Academy of Sciences,
Год журнала:
2024,
Номер
121(51)
Опубликована: Дек. 11, 2024
Inflammation
is
associated
with
localized
acidosis,
however,
attributing
physiological
and
pathological
roles
to
proton-sensitive
receptors
challenging
due
their
diversity
widespread
expression.
Here,
agonists
of
the
proton-sensing
GPCR,
GPR65,
were
systematically
characterized.
The
synthetic
agonist
BTB09089
(BTB)
recapitulated
many
proton-induced
signaling
events
demonstrated
selectivity
for
GPR65.
BTB
was
used
show
that
GPR65
activation
on
fibroblast-like
synoviocytes
(FLS),
cells
line
synovial
joints,
results
in
secretion
proinflammatory
mediators
capable
recruiting
immune
sensitizing
sensory
neurons.
Intra-articular
injection
resulted
GPR65-dependent
sensitization
knee-innervating
neurons
nocifensive
behaviors
mice.
Stimulation
human
FLS
also
triggered
release
inflammatory
fluid
samples
from
osteoarthritis
patients
shown
activate
These
suggest
a
role
mediating
cell-cell
interactions
drive
joint
pain
both
mice
humans.
Antioxidants,
Год журнала:
2024,
Номер
13(7), С. 775 - 775
Опубликована: Июнь 27, 2024
Rheumatoid
arthritis
(RA)
is
a
persistent
autoimmune
disorder
that
characterized
by
joint
inflammation,
discomfort,
and
impairment.
Despite
the
existence
of
several
therapeutic
approaches,
their
effectiveness
often
restricted
may
be
linked
to
unfavorable
side
effects.
Consequently,
there
has
been
growing
interest
in
investigating
naturally
derived
compounds
as
plausible
agents
for
RA
disease.
The
objective
this
review
summarize
existing
preclinical
clinical
evidence
regarding
efficacy
extracted
plant
extracts
treatment
RA,
focusing
on
anti-inflammatory,
anti-oxidative,
immunomodulatory
properties.
Some
problems
with
using
natural
chemicals
are
uneven
quality
commercially
available
preparations
poor
bioavailability
these
compounds.
Future
investigations
should
focus
improving
formulations,
conducting
thorough
trials,
exploring
different
techniques
fully
utilize
intrinsic
potential
treating
RA.
Life,
Год журнала:
2024,
Номер
14(6), С. 751 - 751
Опубликована: Июнь 12, 2024
Rheumatoid
arthritis
(RA)
is
a
systemic
autoimmune
disorder
caused
by
inflammation
of
cartilaginous
diarthrodial
joints
that
destroys
and
cartilage,
resulting
in
synovitis
pannus
formation.
Timely
detection
effective
management
RA
are
pivotal
for
mitigating
inflammatory
consequences,
potentially
influencing
disease
progression.
Nuclear
medicine
using
radiolabeled
targeted
vectors
presents
promising
avenue
diagnosis
response
to
treatment
assessment.
Radiopharmaceutical
such
as
technetium-99m
(
Journal of Pharmaceutical Analysis,
Год журнала:
2024,
Номер
14(11), С. 100981 - 100981
Опубликована: Апрель 22, 2024
Rheumatoid
arthritis
(RA)
is
a
prevalent
autoimmune
disease
characterized
by
chronic
inflammation
and
excessive
proliferation
of
the
synovium.
Currently,
treatment
options
focus
on
either
reducing
or
inhibiting
synovial
hyperplasia.
However,
these
modalities
are
unsatisfactory
in
achieving
desired
therapeutic
outcomes.
Halofuginone
hydrobromide
(HF),
an
herbal
active
ingredient,
has
demonstrated
pharmacological
effects
both
anti-inflammation
inhibition
hyperplasia
proliferation.
HF's
medical
efficacy
limited
due
to
its
poor
water
solubility,
short
half-life,
non-target
toxicity.
In
current
study,
using
advantages
nanotechnology,
we
presented
novel
dual-targeted
nanocomplex,
termed
HA-M@P@HF
NPs,
which
consisted
hyaluronic
acid
(HA)-modified
hybrid
membrane
(M)-camouflaged
poly
lactic-co-glycolic
(PLGA)
nanosystem
for
HF
delivery.
These
nanocomplexes
not
only
overcame
limitations
but
also
achieved
simultaneous
targeting
inflammatory
macrophages
human
fibroblast-like
synoviocytes-rheumatoid
(HFLS-RA).
vivo
experiments
that
effectively
suppressed
immune-mediated
hyperplasia,
safeguarding
against
bone
destruction
rats
with
adjuvant-induced
(AIA).
Remarkable
anti-arthritic
were
accomplished
through
promoting
repolarization
M1-to-M2
apoptosis
HFLS-RA,
thereby
offering
promising
strategy
RA.
bioRxiv (Cold Spring Harbor Laboratory),
Год журнала:
2024,
Номер
unknown
Опубликована: Апрель 30, 2024
Abstract
Inflammation
is
associated
with
localised
acidosis,
however,
attributing
physiological
and
pathological
roles
to
proton-sensitive
receptors
challenging
due
their
diversity
widespread
expression.
Here,
agonists
of
the
proton-sensing
GPCR,
GPR65,
were
systematically
characterised.
The
synthetic
agonist
BTB09089
(BTB)
recapitulated
many
proton-induced
signalling
events
demonstrated
selectivity
for
GPR65.
BTB
was
used
show
that
GPR65
activation
on
fibroblast-like
synoviocytes
(FLS),
cells
line
synovial
joints,
results
in
secretion
pro-inflammatory
mediators
capable
recruiting
immune
sensitising
sensory
neurons.
Intra-articular
injection
resulted
GPR65-dependent
sensitisation
knee-innervating
neurons
nocifensive
behaviours
mice.
Stimulation
human
FLS
also
triggered
release
inflammatory
fluid
samples
from
osteoarthritis
patients
shown
activate
These
suggest
a
role
mediating
cell-cell
interactions
drive
joint
pain
both
mice
humans.
Journal of Nanobiotechnology,
Год журнала:
2024,
Номер
22(1)
Опубликована: Июль 22, 2024
Abstract
Rheumatoid
arthritis
(RA)
involves
chronic
joint
inflammation.
Combining
acupuncture
and
medication
for
RA
treatment
faces
challenges
like
spatiotemporal
variability,
limited
drug
loading
in
needles,
premature
or
untargeted
release.
Here,
we
designed
a
new
type
of
tubular
with
an
etched
hollow
honeycomb-like
structure
to
enable
the
high
therapeutics,
integrating
traditional
repository
into
all-in-one
therapeutic
platform.
In
these
proof-of-concept
experiments,
fabricated
injectable
honeycomb
electroacupuncture
needles
(HC-EA)
loaded
melittin
hydrogel
(MLT-Gel),
enabling
combination
stimulation
therapy
spatiotemporally
synchronous
manner.
Since
microenvironment
is
mildly
acidic,
acid-responsive
chitosan
(CS)/sodium
beta-glycerophosphate
(β-GP)/
hyaluronic
acid
(HA)
composited
(CS/GP/HA)
was
utilized
perform
achieve
targeted
release
injected
therapeutics
specific
lesion
site.
Testing
our
platform
involved
mouse
model
bioinformatics
analysis.
MLT-Gel@HC-EA
restored
Th17/Treg-mediated
immunity
balance,
reduced
inflammatory
factor
(TNF-α,
IL-6,
IL-1β),
alleviated
inflammation
at
This
novel
modified
needle
medication,
specifically
hydrogel,
holds
promise
as
strategy
treatment.
Graphical
abstract
Frontiers in Immunology,
Год журнала:
2024,
Номер
15
Опубликована: Окт. 28, 2024
Rheumatoid
arthritis
(RA)
is
a
chronic
autoimmune
disease
that
causes
joint
inflammation
and
gradual
tissue
destruction.
New
research
has
shown
how
important
noncoding
RNAs
(ncRNAs)
are
for
changing
immune
inflammatory
pathways,
such
as
the
WNT
signaling
pathway,
which
activating
synovial
fibroblasts
osteoblasts
to
work.
This
article
examines
current
understanding
of
several
ncRNAs,
miRNAs,
lncRNAs,
circRNAs,
influence
NF-κB
in
pathogenesis
RA.
We
investigate
these
ncRNAs
impact
components,
altering
cell
proliferation,
differentiation,
death
tissues.
The
paper
also
looks
at
can
be
used
potential
early
detection
markers
therapeutic
targets
RA
because
they
change
pathogenic
pathways.
study
highlights
targeting
therapy
techniques,
with
goal
reducing
stopping
progression.
thorough
analysis
opens
up
new
possibilities
molecular
foundations
designing
novel
ncRNA-based
treatments.
Biomaterials Research,
Год журнала:
2024,
Номер
28
Опубликована: Янв. 1, 2024
Cartilage
repair
is
the
key
to
treatment
of
joint-related
injury.
However,
because
cartilage
lacks
vessels
and
nerves,
its
self-repair
ability
extremely
low.
Extracellular
vesicles
(EVs)
are
bilayer
nanovesicles
with
membranes
mainly
composed
ceramides,
cholesterol,
phosphoglycerides,
long-chain
free
fatty
acids,
containing
DNA,
RNA,
proteins
(such
as
integrins
enzymes).
For
mediating
intercellular
communication
regulating
mechanisms,
EVs
have
been
shown
by
multiple
studies
be
effective
options
for
repair.
This
review
summarizes
recent
findings
different
sources
(mammals,
plants,
bacteria)
uses
in
repair,
mechanisms
captured
injured
chondrocytes,
quantification
storage
EVs,
which
may
provide
scientific
guidance
promoting
development
field
injury
treatment.
Frontiers in Immunology,
Год журнала:
2024,
Номер
15
Опубликована: Март 6, 2024
Rheumatoid
arthritis
(RA)
is
recognized
as
an
autoimmune
joint
disease
driven
by
T
cell
responses
to
self
(or
modified
or
microbial
mimic)
antigens
that
trigger
and
aggravate
the
inflammatory
condition.
Newer
treatments
of
RA
employ
monoclonal
antibodies
recombinant
receptors
against
cytokines
immune
well
small-molecule
Janus
kinase
(JAK)
inhibitors
systemically
ablate
cytokine
cellular
fuel
inflammation.
Unlike
these
treatments,
a
therapeutic
vaccine,
such
CEL-4000,
helps
balance
adaptive
homeostasis
promoting
antigen-specific
regulatory
rather
than
responses,
hence
modulates
immunopathological
course
RA.
In
this
review,
we
discuss
current
proposed
products
for
RA,
with
emphasis
on
vaccine
approaches
treatment
disease.
As
example,
describe
published
results
beneficial
effects
CEL-4000
animal
models
We
also
make
recommendation
design
appropriate
clinical
studies
newest
approaches,
using
example.
vaccines
create
boost
new
response,
success
immunomodulatory
lies
in
its
ability
redirect
autoreactive
pro-inflammatory
memory
cells
towards
rebalancing
“runaway”
immune/inflammatory
characterize
Human
trials
therapy
will
require
alternative
trial
implementation
determining
safety,
toxicity,
efficacy.
These
include
(such
Bayesian
optimal
(BOIN),
currently
employed
oncological
studies),
use
disease-related
biomarkers
indicators
success.
